|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
Winter 2009–2010 2009FeaturesCover Story Stacking Hope Against DollarsWhen it comes to treating cancer, physicians pull out all the stops. In the face of escalating and exorbitant costs, though, what works and what doesn’t must be sorted out. Copay SubsidiesPayers are struggling to find an appropriate way to respond to copayment subsidies. Aggressive tactics to counteract them run the risk of keeping
drugs from people who need them. Cost-Sharing Reform: Searching for EquityThe healthcare reform debate has included discussion of some cost relief for patients by subsidizing their out-of-pocket costs. But employers and payers are looking at other options, such as linking the value of a healthcare intervention to its copayment, to try to improve healthcare delivery and make its cost more equitable for all.
The Impact of the Patient-Centered Medical Home on the Biologics Industry, Employers, and Third-Party PayersA strong primary care system is a critical element of healthcare, but its current state is anything but efficient. One promising model of change is the patient-centered medical home. IOM Likes Its CER List; Others Might if It Suits ThemThe Institute of Medicine, charged with helping health plans and providers choose best treatments, suggests 100 priorities for CER research interest. The use of biologics or the study of biomarkers make up just 4 of the 100 priorities. DepartmentsOpeners Ch... Ch... Changes...
Michael D. Dalzell Editorial Think Globally, Act Locally
David B. Nash, MD, MBA Personalized Medicine KRAS Testing: Optimizing Cancer Therapy
Bob Carlson, MHA Drug Track Research, Conferences, and FDA ActionsSpecialty Pharmacy Mixing Personalized Medicine and CER, One Specialty Pharmacy Plows New GroundTrends Adherence: A Measure of ROI |
|||||